FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy.

ABSTRACT: Evading the antitumor immune response is important for the survival and progression of cancer. Recently, we identified an unexpected role for nuclear Focal Adhesion Kinase (FAK) activity in the control of tumor Treg levels and immune evasion by regulating chemokine and cytokine transcription in cancer cells. We proposed a potentially new purpose for FAK kinase inhibitors, which can cause immune-mediated tumor regression.

SUBMITTER: Serrels A 

PROVIDER: S-EPMC4839353 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature